Рынок лечения легких когнитивных нарушений (ЛКР) в Азиатско-Тихоокеанском регионе – тенденции отрасли и прогноз до 2029 года

Запрос на TOC Запрос на TOC Обратиться к аналитику Обратиться к аналитику Купить сейчас Купить сейчас Узнать перед покупкой Узнать перед покупкой Бесплатный пример отчета Бесплатный пример отчета

Рынок лечения легких когнитивных нарушений (ЛКР) в Азиатско-Тихоокеанском регионе – тенденции отрасли и прогноз до 2029 года

  • Pharmaceutical
  • Published Report
  • Feb 2022
  • Asia-Pacific
  • 350 Pages
  • Количество таблиц: 283
  • Количество рисунков: 53

Рынок лечения легких когнитивных нарушений (MCI) в Азиатско-Тихоокеанском регионе по типу заболевания (амнестический MCI, неамнестический MCI), типу лечения (лекарства, терапия), способу введения (перорально, парентерально, другие), типу препарата (фирменные, дженерики), гендерному типу (мужской, женский), возрастному типу (детский, взрослый, гериатрический), конечному пользователю (больницы, специализированные клиники, уход на дому, другие), каналу распространения (аптеки при больницах, розничная аптека), стране (Китай, Япония, Индия, Южная Корея, Австралия, Сингапур, Таиланд, Малайзия, Индонезия, Вьетнам, Филиппины, остальные страны Азиатско-Тихоокеанского региона) — тенденции отрасли и прогноз до 2029 г.

Рынок лечения легких когнитивных нарушений (MCI) в Азиатско-Тихоокеанском регионе

Анализ рынка и идеи : рынок лечения легких когнитивных нарушений (ЛКР) в Азиатско-Тихоокеанском регионе

Ожидается, что рынок лечения легких когнитивных нарушений (ЛКН) будет расти в прогнозируемый период с 2022 по 2029 год. По данным Data Bridge Market Research, среднегодовой темп роста рынка составит 10,1% в прогнозируемый период с 2022 по 2029 год, и ожидается, что к 2029 году он достигнет 24 974,93 тыс. долларов США. Ожидается, что широкий портфель, предлагаемый основными игроками, и растущая осведомленность о легких когнитивных нарушениях станут движущей силой роста рынка.

Умеренные когнитивные нарушения (УКН) — это ранняя стадия потери памяти или других когнитивных способностей (например, языка или визуального/пространственного восприятия) у людей, которые сохраняют способность выполнять большинство действий в повседневной жизни самостоятельно. УКН может развиться по нескольким причинам, и у людей, живущих с УКН, может развиться деменция. УКН может быть ранней стадией континуума заболеваний нейродегенеративных заболеваний, включая болезнь Альцгеймера. У некоторых людей УКН возвращается к нормальному познанию или остается стабильным.

Умеренное когнитивное нарушение (УКН) характеризуется нарушением в одной когнитивной области, обычно памяти (амнестическое УКН), или умеренным нарушением в нескольких когнитивных областях. Распространенность УКН среди лиц, живущих в учреждениях длительного ухода, варьируется от 5% до 10% во многих домах престарелых и до 30%. Наиболее часто встречающаяся форма УКН — амнестический тип. Менее распространенные варианты УКН проявляются локализованным нарушением других когнитивных областей, таким как исполнительная дисфункция при лобно-височной лобарной дегенерации (ФТЛД).

Основными факторами, обуславливающими рост мирового рынка лечения легких когнитивных нарушений (MCI), являются увеличение популяции пожилых пациентов, продолжающиеся исследования по поиску идеального и эффективного лечения, как ожидается, будут способствовать росту рынка в будущем. Однако высокая стоимость процедур терапии и сопутствующие продукты неблагоприятные риски могут сдерживать рост рынка.

Отчет о рынке лечения легких когнитивных нарушений (MCI) содержит подробную информацию о доле рынка, новых разработках и анализе продуктового портфеля, влиянии внутренних и локальных игроков рынка, анализирует возможности с точки зрения новых источников дохода, изменений в рыночных правилах, одобрений продуктов, стратегических решений, запусков продуктов, географических расширений и технологических инноваций на рынке. Чтобы понять анализ и сценарий рынка лечения легких когнитивных нарушений (MCI), свяжитесь с Data Bridge Market Research для получения аналитического обзора, наша команда поможет вам создать решение по влиянию на доход для достижения желаемой цели.

Рынок лечения легких когнитивных нарушений (MCI) в Азиатско-Тихоокеанском регионе

Масштаб рынка лечения легких когнитивных нарушений (ЛКР) и размер рынка

Рынок лечения легких когнитивных нарушений (MCI) сегментирован на основе типа заболевания, типа лечения, пути введения, типа препарата, пола, возраста, канала сбыта и конечных пользователей. Рост среди сегментов помогает вам анализировать нишевые очаги роста и стратегии выхода на рынок и определять ваши основные области применения и разницу в ваших целевых рынках.

  • В зависимости от типа заболевания рынок лечения легких когнитивных нарушений (MCI) сегментируется на амнестические MCI и неамнестические MCI. Ожидается, что в 2022 году сегмент амнестических MCI будет доминировать на мировом рынке лечения легких когнитивных нарушений (MCI) из-за увеличения численности пожилого населения во всем мире.
  • Рынок лечения легких когнитивных нарушений (MCI) сегментируется по типу лечения на медикаментозное и терапевтическое. Ожидается, что в 2022 году сегмент медикаментов будет доминировать на мировом рынке лечения легких когнитивных нарушений (MCI) из-за его немедленного и эффективного воздействия на симптомы MCI.
  • Рынок лечения легких когнитивных нарушений (MCI) по способу введения сегментируется на пероральный, парентеральный и другие. Ожидается, что в 2022 году пероральный сегмент будет доминировать на мировом рынке лечения легких когнитивных нарушений (MCI) из-за неинвазивности, высокой степени соответствия пациентов лечению, удобства в обращении и отсутствия необходимости в каких-либо особых стерильных условиях.
  • Рынок лечения легких когнитивных нарушений (MCI) сегментируется на основе типа препарата на брендовые и дженерики. Ожидается, что в 2022 году сегмент дженериков будет доминировать на мировом рынке лечения легких когнитивных нарушений (MCI) из-за экономической эффективности по сравнению с брендовыми препаратами.
  • По половому признаку рынок лечения легких когнитивных нарушений (MCI) сегментируется на мужской и женский. Ожидается, что в 2022 году мужской сегмент будет доминировать на мировом рынке лечения легких когнитивных нарушений (MCI) из-за всплеска осложнений психического здоровья, наблюдаемых среди мужского населения.
  • Рынок лечения легких когнитивных нарушений (MCI) сегментируется по возрасту на детский, взрослый и гериатрический. Ожидается, что в 2022 году гериатрический сегмент будет доминировать на мировом рынке лечения легких когнитивных нарушений (MCI) из-за резкого увеличения уязвимой популяции пожилых людей с самыми высокими темпами роста в Азиатском регионе.
  • На основе конечных пользователей рынок лечения легких когнитивных нарушений (MCI) сегментируется на больницы, специализированные клиники, уход на дому и т. д. Ожидается, что в 2022 году больничный сегмент будет доминировать на мировом рынке лечения легких когнитивных нарушений (MCI) из-за возросшей осведомленности о лучшем и более эффективном лечении во время пребывания в больнице.
  • Рынок лечения легких когнитивных нарушений (MCI) по каналу сбыта сегментируется на больничные аптеки, розничные аптеки. Ожидается, что в 2022 году сегмент больничных аптек будет доминировать на мировом рынке лечения легких когнитивных нарушений (MCI) за счет расширения взаимодействия с сертифицированными врачами и специалистами здравоохранения для использования антипсихотических препаратов и гарантированной оплаты.

Анализ рынка лечения легких когнитивных нарушений на уровне страны

Проанализирован рынок лечения легких когнитивных нарушений (ЛКР) и предоставлена ​​информация о размере рынка по стране, типу заболевания, типу лечения, пути введения, типу препарата, полу, возрасту, каналу сбыта и конечным пользователям, как указано выше.

В отчете о рынке лечения легких когнитивных нарушений (ЛКР) рассматриваются следующие страны: Китай, Южная Корея, Япония, Индия, Австралия, Сингапур, Вьетнам, Малайзия, Индонезия, Таиланд, Филиппины и остальные страны Азиатско-Тихоокеанского региона.

Ожидается, что Китай будет доминировать на рынке лечения легких когнитивных расстройств (ЛКР) в Азиатско-Тихоокеанском регионе из-за растущего числа пожилых людей в стране.

Раздел отчета по странам также содержит отдельные факторы, влияющие на рынок, и изменения в регулировании на внутреннем рынке, которые влияют на текущие и будущие тенденции рынка. Такие данные, как новые продажи, замещающие продажи, демографические данные страны, нормативные акты и импортно-экспортные тарифы, являются одними из основных указателей, используемых для прогнозирования рыночного сценария для отдельных стран. Кроме того, при предоставлении прогнозного анализа данных по стране учитываются наличие и доступность глобальных брендов и их проблемы из-за большой или малой конкуренции со стороны местных и отечественных брендов, влияние каналов продаж.

Расширение стратегических мероприятий со стороны основных участников рынка по повышению осведомленности о лечении легких когнитивных нарушений (ЛКР) стимулирует рост рынка лечения легких когнитивных нарушений (ЛКР).

Рынок лечения легких когнитивных нарушений (MCI) также предоставляет вам подробный анализ рынка для роста каждой страны на определенном рынке. Кроме того, он предоставляет подробную информацию о стратегии участников рынка и их географическом присутствии. Данные доступны за исторический период с 2011 по 2020 год.

Анализ конкурентной среды и доли рынка лечения легких когнитивных нарушений (ЛКР)

Конкурентная среда рынка лечения легких когнитивных нарушений (MCI) содержит сведения по конкурентам. Включены сведения о компании, финансы компании, полученный доход, рыночный потенциал, инвестиции в исследования и разработки, новые рыночные инициативы, производственные площадки и объекты, сильные и слабые стороны компании, запуск продукта, испытания продуктов, одобрения продуктов, патенты, широта и широта продукта, доминирование приложений, кривая жизненной линии технологий. Приведенные выше данные относятся только к фокусу компании, связанному с рынком лечения легких когнитивных нарушений (MCI).

Некоторые из основных игроков, работающих на рынке лечения легких когнитивных нарушений (ЛКН), включают Pfizer Inc., F. Hoffman La Roche Ltd, Novartis AG, Accord UK Ltd, Dr. Reddy's Laboratories Ltd, Hikma Pharmaceuticals PLC, Viatris Inc., Eisai. Co. Ltd., Sun Pharmaceuticals ltd., Johnson & Johnson Services, Inc., Teva Pharmaceutical Industries Ltd., Mallinckrodt, AstraZeneca, Cipla Inc., Takeda Pharmaceutical Company Limited, Allergan Aesthetics, Lupin, Jubilant Pharmova Limited, Lannett, Aurobindo Pharma, UCB SA, Belgium и WOCKHARDT, а также другие.

Например,

  • В июле 2021 года FDA одобрило препарат Biogen Aduhelm (адуканумаб) для лечения пациентов с болезнью Альцгеймера с использованием ускоренного пути одобрения.

Сотрудничество, запуск продукции, расширение бизнеса, награды и признание, совместные предприятия и другие стратегии участников рынка расширяют присутствие компании на рынке лечения легких когнитивных нарушений (ЛКР), что также обеспечивает рост прибыли организации.


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Интерактивная панель анализа данных
  • Панель анализа компании для возможностей с высоким потенциалом роста
  • Доступ аналитика-исследователя для настройки и запросов
  • Анализ конкурентов с помощью интерактивной панели
  • Последние новости, обновления и анализ тенденций
  • Используйте возможности сравнительного анализа для комплексного отслеживания конкурентов
Запросить демонстрацию

Содержание

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 MARKET END USERS COVERAGE GRID

2.8 DISEASES TYPE LIFELINE CURVE

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTLE

4.2 PORTERS

5 EPIDEMIOLOGY

6 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: REGULATORY SCENARIO

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 INCREASE IN VULNERABLE GERIATRIC POPULATION

7.1.2 INCREASE IN AIR POLLUTION IMPACTS COGNITIVE PERFORMANCE

7.1.3 INCREASING NATIONAL AND INTERNATIONAL INVESTMENTS IN RESEARCH AND DEVELOPMENT OF COGNITIVE DISORDERS TREATMENT

7.1.4 RISE IN INCIDENCE OF NON-COMMUNICABLE DISEASES DUE TO PHYSICAL INACTIVITY

7.2 RESTRAINTS

7.2.1 UNAVAILABILITY OF ANY SPECIFIC TREATMENT

7.2.2 SERIOUS ADVERSE RISK ASSOCIATED WITH MCI TREATMENT DRUGS

7.2.3 HIGH COST OF TREATMENT AND CARE MANAGEMENT IN MCI PATIENTS

7.3 OPPORTUNITIES

7.3.1 PROMOTING PATIENT MENTAL HEALTH PROGRAMS

7.3.2 INNOVATION IN ALTERNATIVE MILD COGNITIVE IMPAIRMENT TREATMENT

7.4 CHALLENGES

7.4.1 LONG PROCESS OF APPROVAL BY REGULATORY BODIES

7.4.2 LACK OF SKILLED PROFESSIONALS

8 COVID-19 IMPACT ON MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET

8.1 PRICE IMPACT

8.2 IMPACT ON DEMAND

8.3 IMPACT ON SUPPLY

8.4 STRATEGIC DECISIONS BY MANUFACTURERS

8.5 CONCLUSION

9 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE

9.1 OVERVIEW

9.2 AMNESTIC MCI

9.3 NON-AMNESTIC MCI

10 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT

10.1 OVERVIEW

10.2 MEDICATION

10.2.1 CHOLINESTERASE INHIBITORS

10.2.1.1 DONEPEZIL

10.2.1.2 RIVASTIGMINE

10.2.1.3 OTHERS

10.2.2 BENZODIAZEPINES

10.2.2.1 DIAZEPAM

10.2.2.2 CLONAZEPAM

10.2.2.3 LORAZEPAM

10.2.2.4 TEMAZEPAM

10.2.2.5 ALPRAZOLAM

10.2.2.6 FLUNITRAZEPAM

10.2.2.7 FLURAZEPAM

10.2.2.8 ZOPICLONE

10.2.2.9 OTHERS

10.2.3 GLUTAMATE INHIBITORS

10.2.3.1 RILUZOLE

10.2.3.2 OTHERS

10.2.4 ANTIHISTAMINES

10.2.4.1 CETIRIZINE

10.2.4.2 BROMPHENIRAMINE

10.2.4.3 CHLORPHENIRAMINE

10.2.4.4 CLEMASTINE

10.2.4.5 DIPHENHYDRAMINE

10.2.4.6 FEXOFENADINE

10.2.4.7 LORATADINE

10.2.4.8 OTHERS

10.2.5 MAO INHIBITORS

10.2.5.1 ISOCARBOXAZID

10.2.5.2 PHENELZINE

10.2.5.3 SELEGILINE

10.2.5.4 TRANYLCYPROMINE

10.2.5.5 OTHERS

10.2.6 PROTON PUMP INHIBITORS

10.2.6.1 ESOMEPRAZOLE

10.2.6.2 LANSOPRAZOLE

10.2.6.3 OMEPRAZOLE

10.2.6.4 RABEPRAZOLE

10.2.6.5 PANTOPRAZOLE

10.2.6.6 OTHERS

10.2.7 ALTERNATE THERAPY

10.2.7.1 VITAMIN E

10.2.7.2 GINKO

10.2.7.3 OTHERS

10.2.7.4 OTHERS

10.3 THERAPY

10.3.1 COGNITIVE STIMULATION THERAPY

10.3.2 COGNITIVE BEHAVIORAL THERAPY (CBT)

11 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

11.1 OVERVIEW

11.2 ORAL

11.2.1 TABLET

11.2.2 SYRUP

11.2.3 OTHERS

11.3 PARENTERAL

11.3.1 INTRAVENOUS

11.3.2 INTRAMUSCULAR

11.3.3 OTHERS

11.4 OTHERS

12 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE

12.1 OVERVIEW

12.2 GENERICS

12.3 BRANDED

13 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER

13.1 OVERVIEW

13.2 MALE

13.3 FEMALE

14 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE

14.1 OVERVIEW

14.2 GERIATRIC

14.3 ADULT

14.4 CHILD

15 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER

15.1 OVERVIEW

15.2 HOSPITALS

15.3 SPECIALTY CLINICS

15.4 HOMECARE

15.5 OTHERS

16 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL

16.1 OVERVIEW

16.2 HOSPITAL PHARMACY

16.3 RETAIL PHARMACY

16.3.1 RETAIL SHOPS

16.3.2 ONLINE PHARMACY

17 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION

17.1 ASIA-PACIFIC

17.1.1 CHINA

17.1.2 JAPAN

17.1.3 INDIA

17.1.4 SOUTH KOREA

17.1.5 AUSTRALIA

17.1.6 SINGAPORE

17.1.7 THAILAND

17.1.8 INDONESIA

17.1.9 PHILIPPINES

17.1.10 MALAYSIA

17.1.11 VIETNAM

17.1.12 REST OF ASIA-PACIFIC

18 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: COMPANY LANDSCAPE

18.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC

19 SWOT ANALYSIS

20 COMPANY PROFILE

20.1 EISAI CO., LTD

20.1.1 COMPANY SNAPSHOT

20.1.2 REVENUE ANALYSIS

20.1.3 COMPANY SHARE ANALYSIS

20.1.4 PRODUCT PORTFOLIO

20.1.5 RECENT DEVELOPMENTS

20.1.5.1 PRODUCT LAUNCH

20.2 TEVA PHARMACEUTICAL INDUSTRIES LTD

20.2.1 COMPANY SNAPSHOT

20.2.2 REVENUE ANALYSIS

20.2.3 COMPANY SHARE ANALYSIS

20.2.4 PRODUCT PORTFOLIO

20.2.5 RECENT DEVELOPMENT

20.3 NOVARTIS AG

20.3.1 COMPANY SNAPSHOT

20.3.2 REVENUE ANALYSIS

20.3.3 COMPANY SHARE ANALYSIS

20.3.4 PRODUCT PORTFOLIO

20.3.5 RECENT DEVELOPMENT

20.4 VIATRIS, INC

20.4.1 COMPANY SNAPSHOT

20.4.2 REVENUE ANALYSIS

20.4.3 COMPANY SHARE ANALYSIS

20.4.4 PRODUCT PORTFOLIO

20.4.5 RECENT DEVELOPMENT

20.5 SUN PHARMACEUTICALS INDUSTRIES LTD

20.5.1 COMPANY SNAPSHOT

20.5.2 REVENUE ANALYSIS

20.5.3 COMPANY SHARE ANALYSIS

20.5.4 PRODUCT PORTFOLIO

20.5.5 RECENT DEVELOPMENT

20.6 PFIZER INC.

20.6.1 COMPANY SNAPSHOT

20.6.2 REVENUE ANALYSIS

20.6.3 PRODUCT PORTFOLIO

20.6.4 RECENT DEVELOPMENT

20.7 ASTRAZENECA

20.7.1 COMPANY SNAPSHOT

20.7.2 REVENUE ANALYSIS

20.7.3 PRODUCT PORTFOLIO

20.7.4 RECENT DEVELOPMENT

20.7.4.1 ACQUISITION

20.8 DR. REDDY’S LABORATORIES LTD.

20.8.1 COMPANY SNAPSHOT

20.8.2 REVENUE ANALYSIS

20.8.3 PRODUCT PORTFOLIO

20.8.4 RECENT DEVELOPMENTS

20.9 AUROBINDO PHARMA

20.9.1 COMPANY SNAPSHOT

20.9.2 REVENUE ANALYSIS

20.9.3 PRODUCT PORFOLIO

20.9.4 RECENT DEVELOPMENT

20.9.4.1 PRODUCT APPROVAL

20.1 F.HOFFMANN-LA ROCHE LTD.

20.10.1 COMPANY SNAPSHOT

20.10.2 REVENUE ANALYSIS

20.10.3 PRODUCT PORTFOLIO

20.10.4 RECENT DEVELOPMENT

20.11 ABBVIE INC.

20.11.1 COMPANY SNAPSHOT

20.11.2 REVENUE ANALYSIS

20.11.3 PRODUCT PORTFOLIO

20.11.4 RECENT DEVELOPMENT

20.11.4.1 DATA PRESENTATION

20.12 ACCORD-UK LTD

20.12.1 COMPANY SNAPSHOT

20.12.2 PRODUCT PORTFOLIO

20.12.3 RECENT DEVELOPMENT

20.13 CIPLA INC.

20.13.1 COMPANY SNAPSHOT

20.13.2 REVENUE ANALYSIS

20.13.3 PRODUCT PORTFOLIO

20.13.4 RECENT DEVELOPMENT

20.14 HIKMA PHARMACEUTICALS PLC

20.14.1 COMPANY SNAPSHOT

20.14.2 REVENUE ANALYSIS

20.14.3 PRODUCT PORTFOLIO

20.14.4 RECENT DEVELOPMENTS

20.15 JOHNSON & JOHNSON SERVICES, INC.

20.15.1 COMPANY SNAPSHOT

20.15.2 REVENUE ANALYSIS

20.15.3 PRODUCT PORTFOLIO

20.15.4 RECENT DEVELOPMENT

20.16 JUBILANT PHARMA LIMITED

20.16.1 COMPANY SNAPSHOT

20.16.2 REVENUE ANALYSIS

20.16.3 PRODUCT PORTFOLIO

20.16.4 RECENT DEVELOPMENT

20.17 LANNETT

20.17.1 COMPANY SNAPSHOT

20.17.2 REVENUE ANALYSIS

20.17.3 PRODUCT PORTFOLIO

20.17.4 RECENT DEVELOPMENT

20.18 LUPIN

20.18.1 COMPANY SNAPSHOT

20.18.2 REVENUE ANALYSIS

20.18.3 PRODUCT PORTFOLIO

20.18.4 RECENT DEVELOPMENT

20.18.4.1 AGREEMENT

20.19 MALLINCKRODT PHARMACEUTICALS

20.19.1 COMPANY SNAPSHOT

20.19.2 REVENUE ANALYSIS

20.19.3 PRODUCT PORTFOLIO

20.19.4 RECENT DEVELOPMENT

20.2 TAKEDA PHARMACEUTICAL COMPANY LIMITED

20.20.1 COMPANY SNAPSHOT

20.20.2 REVENUE ANALYSIS

20.20.3 PRODUCT PORTFOLIO

20.20.4 RECENT DEVELOPMENT

20.21 UCB S.A., BELGIUM

20.21.1 COMPANY SNAPSHOT

20.21.2 REVENUE ANALYSIS

20.21.3 PRODUCT PORTFOLIO

20.21.4 RECENT DEVELOPMENT

20.22 WOCKHARDT

20.22.1 COMPANY SNAPSHOT

20.22.2 REVENUE ANALYSIS

20.22.3 PRODUCT PORTFOLIO

20.22.4 RECENT DEVELOPMENT

21 QUESTIONNAIRE

22 RELATED REPORTS

Список таблиц

TABLE 1 COMMON BENZODIAZEPINES AVAILABLE IN THE U.S.-

TABLE 2 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)

TABLE 3 ASIA PACIFIC AMNESTIC MCI IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 4 ASIA PACIFIC NON-AMNESTIC MCI IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 5 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 6 ASIA PACIFIC MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 7 ASIA PACIFIC MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 8 ASIA PACIFIC CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 9 ASIA PACIFIC BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 10 ASIA PACIFIC GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 11 ASIA PACIFIC ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 12 ASIA PACIFIC MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 13 ASIA PACIFIC PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 14 ASIA PACIFIC ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 15 ASIA PACIFIC THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 16 ASIA PACIFIC THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 17 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 18 ASIA PACIFIC ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 19 ASIA PACIFIC ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 20 ASIA PACIFIC PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 21 ASIA PACIFIC PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 22 ASIA PACIFIC OTHERS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 23 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)

TABLE 24 ASIA PACIFIC GENERICS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 25 ASIA PACIFIC BRANDED IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 26 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)

TABLE 27 ASIA PACIFIC MALE IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 28 ASIA PACIFIC FEMALE IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 29 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 30 ASIA PACIFIC GERIATRIC IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 31 ASIA PACIFIC ADULT IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 32 ASIA PACIFIC CHILD IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 33 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 34 ASIA PACIFIC HOSPITALS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 35 ASIA PACIFIC SPECIALITY CLINICS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 36 ASIA PACIFIC HOMECARE IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 37 ASIA PACIFIC OTHERS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 38 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 39 ASIA PACIFIC HOSPITAL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 40 ASIA PACIFIC RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY REGION, 2020-2029 (USD THOUSAND)

TABLE 41 ASIA PACIFIC RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 42 ASIA-PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY COUNTRY, 2020-2029 (USD THOUSAND)

TABLE 43 ASIA-PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)

TABLE 44 ASIA-PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 45 ASIA-PACIFIC MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 46 ASIA-PACIFIC CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 47 ASIA-PACIFIC BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 48 ASIA-PACIFIC GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 49 ASIA-PACIFIC MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 50 ASIA-PACIFIC PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 51 ASIA-PACIFIC ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 52 ASIA-PACIFIC ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 53 ASIA-PACIFIC THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 54 ASIA-PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 55 ASIA-PACIFIC ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 56 ASIA-PACIFIC PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 57 ASIA-PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)

TABLE 58 ASIA-PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)

TABLE 59 ASIA-PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 60 ASIA-PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 61 ASIA-PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 62 ASIA-PACIFIC RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 63 CHINA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)

TABLE 64 CHINA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 65 CHINA MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 66 CHINA CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 67 CHINA BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 68 CHINA GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 69 CHINA MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 70 CHINA PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 71 CHINA ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 72 CHINA ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 73 CHINA THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 74 CHINA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 75 CHINA ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 76 CHINA PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 77 CHINA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)

TABLE 78 CHINA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)

TABLE 79 CHINA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 80 CHINA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 81 CHINA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 82 CHINA RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 83 JAPAN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)

TABLE 84 JAPAN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 85 JAPAN MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 86 JAPAN CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 87 JAPAN BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 88 JAPAN GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 89 JAPAN MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 90 JAPAN PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 91 JAPAN ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 92 JAPAN ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 93 JAPAN THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 94 JAPAN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 95 JAPAN ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 96 JAPAN PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 97 JAPAN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)

TABLE 98 JAPAN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)

TABLE 99 JAPAN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 100 JAPAN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 101 JAPAN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 102 JAPAN RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 103 INDIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)

TABLE 104 INDIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 105 INDIA MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 106 INDIA CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 107 INDIA BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 108 INDIA GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 109 INDIA MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 110 INDIA PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 111 INDIA ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 112 INDIA ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 113 INDIA THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 114 INDIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 115 INDIA ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 116 INDIA PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 117 INDIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)

TABLE 118 INDIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)

TABLE 119 INDIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 120 INDIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 121 INDIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 122 INDIA RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 123 SOUTH KOREA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)

TABLE 124 SOUTH KOREA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 125 SOUTH KOREA MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 126 SOUTH KOREA CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 127 SOUTH KOREA BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 128 SOUTH KOREA GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 129 SOUTH KOREA MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 130 SOUTH KOREA PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 131 SOUTH KOREA ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 132 SOUTH KOREA ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 133 SOUTH KOREA THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 134 SOUTH KOREA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 135 SOUTH KOREA ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 136 SOUTH KOREA PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 137 SOUTH KOREA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)

TABLE 138 SOUTH KOREA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)

TABLE 139 SOUTH KOREA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 140 SOUTH KOREA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 141 SOUTH KOREA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 142 SOUTH KOREA RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 143 AUSTRALIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)

TABLE 144 AUSTRALIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 145 AUSTRALIA MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 146 AUSTRALIA CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 147 AUSTRALIA BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 148 AUSTRALIA GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 149 AUSTRALIA MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 150 AUSTRALIA PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 151 AUSTRALIA ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 152 AUSTRALIA ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 153 AUSTRALIA THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 154 AUSTRALIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 155 AUSTRALIA ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 156 AUSTRALIA PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 157 AUSTRALIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)

TABLE 158 AUSTRALIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)

TABLE 159 AUSTRALIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 160 AUSTRALIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 161 AUSTRALIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 162 AUSTRALIA RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 163 SINGAPORE MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)

TABLE 164 SINGAPORE MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 165 SINGAPORE MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 166 SINGAPORE CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 167 SINGAPORE BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 168 SINGAPORE GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 169 SINGAPORE MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 170 SINGAPORE PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 171 SINGAPORE ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 172 SINGAPORE ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 173 SINGAPORE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 174 SINGAPORE MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 175 SINGAPORE ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 176 SINGAPORE PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 177 SINGAPORE MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)

TABLE 178 SINGAPORE MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)

TABLE 179 SINGAPORE MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 180 SINGAPORE MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 181 SINGAPORE MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 182 SINGAPORE RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 183 THAILAND MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)

TABLE 184 THAILAND MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 185 THAILAND MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 186 THAILAND CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 187 THAILAND BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 188 THAILAND GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 189 THAILAND MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 190 THAILAND PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 191 THAILAND ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 192 THAILAND ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 193 THAILAND THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 194 THAILAND MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 195 THAILAND ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 196 THAILAND PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 197 THAILAND MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)

TABLE 198 THAILAND MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)

TABLE 199 THAILAND MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 200 THAILAND MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 201 THAILAND MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 202 THAILAND RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 203 INDONESIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)

TABLE 204 INDONESIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 205 INDONESIA MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 206 INDONESIA CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 207 INDONESIA BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 208 INDONESIA GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 209 INDONESIA MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 210 INDONESIA PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 211 INDONESIA ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 212 INDONESIA ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 213 INDONESIA THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 214 INDONESIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 215 INDONESIA ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 216 INDONESIA PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 217 INDONESIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)

TABLE 218 INDONESIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)

TABLE 219 INDONESIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 220 INDONESIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 221 INDONESIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 222 INDONESIA RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 223 PHILIPPINES MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)

TABLE 224 PHILIPPINES MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 225 PHILIPPINES MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 226 PHILIPPINES CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 227 PHILIPPINES BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 228 PHILIPPINES GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 229 PHILIPPINES MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 230 PHILIPPINES PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 231 PHILIPPINES ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 232 PHILIPPINES ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 233 PHILIPPINES THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 234 PHILIPPINES MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 235 PHILIPPINES ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 236 PHILIPPINES PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 237 PHILIPPINES MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)

TABLE 238 PHILIPPINES MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)

TABLE 239 PHILIPPINES MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 240 PHILIPPINES MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 241 PHILIPPINES MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 242 PHILIPPINES RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 243 MALAYSIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)

TABLE 244 MALAYSIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 245 MALAYSIA MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 246 MALAYSIA CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 247 MALAYSIA BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 248 MALAYSIA GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 249 MALAYSIA MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 250 MALAYSIA PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 251 MALAYSIA ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 252 MALAYSIA ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 253 MALAYSIA THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 254 MALAYSIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 255 MALAYSIA ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 256 MALAYSIA PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 257 MALAYSIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)

TABLE 258 MALAYSIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)

TABLE 259 MALAYSIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 260 MALAYSIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 261 MALAYSIA MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 262 MALAYSIA RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 263 VIETNAM MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)

TABLE 264 VIETNAM MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 265 VIETNAM MEDICATION IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 266 VIETNAM CHOLINESTERASE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 267 VIETNAM BENZODIAZEPINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 268 VIETNAM GLUTAMATE INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 269 VIETNAM MAO INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 270 VIETNAM PROTON PUMP INHIBITORS IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 271 VIETNAM ANTIHISTAMINES IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 272 VIETNAM ALTERNATE THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 273 VIETNAM THERAPY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY TREATMENT, 2020-2029 (USD THOUSAND)

TABLE 274 VIETNAM MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 275 VIETNAM ORAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 276 VIETNAM PARENTERAL IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

TABLE 277 VIETNAM MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DRUG TYPE, 2020-2029 (USD THOUSAND)

TABLE 278 VIETNAM MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY GENDER, 2020-2029 (USD THOUSAND)

TABLE 279 VIETNAM MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY AGE, 2020-2029 (USD THOUSAND)

TABLE 280 VIETNAM MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY END USER, 2020-2029 (USD THOUSAND)

TABLE 281 VIETNAM MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 282 VIETNAM RETAIL PHARMACY IN MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

TABLE 283 REST OF ASIA-PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET, BY DISEASE TYPE, 2020-2029 (USD THOUSAND)

Список рисунков

FIGURE 1 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: SEGMENTATION

FIGURE 2 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: DATA TRIANGULATION

FIGURE 3 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS

FIGURE 5 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: END USERS COVERAGE GRID

FIGURE 8 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 9 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: SEGMENTATION

FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE AND ASIA-PACIFIC IS ESTIMATED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 ONGOING RESEARCH TO INCREASE THE THERAPEUTICS APPLICATION IS EXPECTED TO DRIVE THE ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 13 AMNESTIC MCI SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET IN 2022 & 2029

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET

FIGURE 15 DISEASE BURDEN BY RISK FACTOR, WORLDWIDE, 2019

FIGURE 16 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISEASE TYPE, 2021

FIGURE 17 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISEASE TYPE, 2020-2029 (USD THOUSAND)

FIGURE 18 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISEASE TYPE, CAGR (2022-2029)

FIGURE 19 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISEASE TYPE, LIFELINE CURVE

FIGURE 20 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY TREATMENT, 2021

FIGURE 21 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY TREATMENT, 2020-2029 (USD THOUSAND)

FIGURE 22 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY TREATMENT, CAGR (2022-2029)

FIGURE 23 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE

FIGURE 24 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2021

FIGURE 25 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2029 (USD THOUSAND)

FIGURE 26 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)

FIGURE 27 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 28 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DRUG TYPE, 2021

FIGURE 29 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DRUG TYPE, 2020-2029 (USD THOUSAND)

FIGURE 30 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DRUG TYPE, CAGR (2022-2029)

FIGURE 31 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DRUG TYPE, LIFELINE CURVE

FIGURE 32 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY GENDER, 2021

FIGURE 33 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY GENDER, 2020-2029 (USD THOUSAND)

FIGURE 34 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY GENDER, CAGR (2022-2029)

FIGURE 35 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY GENDER, LIFELINE CURVE

FIGURE 36 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY AGE, 2021

FIGURE 37 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY AGE, 2020-2029 (USD THOUSAND)

FIGURE 38 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY AGE, CAGR (2022-2029)

FIGURE 39 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY AGE, LIFELINE CURVE

FIGURE 40 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY END USER, 2021

FIGURE 41 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY END USER, 2020-2029 (USD THOUSAND)

FIGURE 42 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY END USER, CAGR (2022-2029)

FIGURE 43 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY END USER, LIFELINE CURVE

FIGURE 44 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 45 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020-2029 (USD THOUSAND)

FIGURE 46 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 47 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 48 ASIA-PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: SNAPSHOT (2021)

FIGURE 49 ASIA-PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY COUNTRY (2021)

FIGURE 50 ASIA-PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY COUNTRY (2022 & 2029)

FIGURE 51 ASIA-PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY COUNTRY (2021 & 2029)

FIGURE 52 ASIA-PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: BY DISEASE TYPE (2022-2029)

FIGURE 53 ASIA PACIFIC MILD COGNITIVE IMPAIRMENT (MCI) TREATMENT MARKET: COMPANY SHARE 2021 (%)

View Detailed Information Right Arrow

Методология исследования

Сбор данных и анализ базового года выполняются с использованием модулей сбора данных с большими размерами выборки. Этап включает получение рыночной информации или связанных данных из различных источников и стратегий. Он включает изучение и планирование всех данных, полученных из прошлого заранее. Он также охватывает изучение несоответствий информации, наблюдаемых в различных источниках информации. Рыночные данные анализируются и оцениваются с использованием статистических и последовательных моделей рынка. Кроме того, анализ доли рынка и анализ ключевых тенденций являются основными факторами успеха в отчете о рынке. Чтобы узнать больше, пожалуйста, запросите звонок аналитика или оставьте свой запрос.

Ключевой методологией исследования, используемой исследовательской группой DBMR, является триангуляция данных, которая включает в себя интеллектуальный анализ данных, анализ влияния переменных данных на рынок и первичную (отраслевую экспертную) проверку. Модели данных включают сетку позиционирования поставщиков, анализ временной линии рынка, обзор рынка и руководство, сетку позиционирования компании, патентный анализ, анализ цен, анализ доли рынка компании, стандарты измерения, глобальный и региональный анализ и анализ доли поставщика. Чтобы узнать больше о методологии исследования, отправьте запрос, чтобы поговорить с нашими отраслевыми экспертами.

Доступна настройка

Data Bridge Market Research является лидером в области передовых формативных исследований. Мы гордимся тем, что предоставляем нашим существующим и новым клиентам данные и анализ, которые соответствуют и подходят их целям. Отчет можно настроить, включив в него анализ ценовых тенденций целевых брендов, понимание рынка для дополнительных стран (запросите список стран), данные о результатах клинических испытаний, обзор литературы, обновленный анализ рынка и продуктовой базы. Анализ рынка целевых конкурентов можно проанализировать от анализа на основе технологий до стратегий портфеля рынка. Мы можем добавить столько конкурентов, о которых вам нужны данные в нужном вам формате и стиле данных. Наша команда аналитиков также может предоставить вам данные в сырых файлах Excel, сводных таблицах (книга фактов) или помочь вам в создании презентаций из наборов данных, доступных в отчете.

Часто задаваемые вопросы

Asia-Pacific Mild Cognitive Impairment (MCI) Treatment Market is growing with a CAGR of 10.1% by 2029.
Asia-Pacific Mild Cognitive Impairment (MCI) Treatment Market is expected to reach USD 24,974.93 thousand by 2029.
The mild cognitive impairment (MCI) treatment market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market.
the major players operating in the mild cognitive impairment (MCI) treatment market are Pfizer Inc., F. Hoffman La Roche Ltd, Novartis AG, Accord UK Ltd, Dr. Reddy’s laboratories Ltd, Hikma Pharmaceuticals PLC, Viatris Inc., Eisai. Co. Ltd., Sun Pharmaceuticals ltd., Johnson & Johnson Services, Inc., Teva Pharmaceutical Industries Ltd., Mallinckrodt, AstraZeneca, Cipla Inc., Takeda Pharmaceutical Company Limited, Allergan Aesthetics, Lupin, Jubilant Pharmova Limited, Lannett, Aurobindo Pharma, UCB S.A., Belgium, and WOCKHARDT, among others.